Research being presented at ASHG 2020 to support use of PTA technology in the study of genetic variants that contribute to drug resistance in cancer treatment
BioSkryb, Inc., a developer of genomic amplification technologies, today announced the commercial launch of ResolveDNATM products to accurately and uniformly reproduce genomes of single cells. The ResolveDNA product line incorporates novel primary template-directed amplification (PTA) technology, which captures more than 95% of the genomes of single cells to provide high-quality, scalable analysis of single-cell genomic heterogeneity. This proprietary technology will enable new insights into human disease at the cellular level. To hear more about the now commercially available ResolveDNA suite of products, visit BioSkryb’s virtual booth at ASHG 2020.
BioSkryb also announced a scientific poster presentation demonstrating the use of PTA technology to study genetic variants that drive therapeutic resistance. The poster, which received a Reviewer’s Choice award, is entitled, "Primary template-directed amplification for single-cell elucidation of targeted therapy resistance mechanisms in acute myeloid leukemia and triple-negative breast cancer," and is available for viewing at ASHG 2020 (Session 202: Cancer, Abstract 2406).
"Single-cell approaches are imperative to understanding, diagnosing, and treating human diseases involving genomic heterogeneity, like cancer," said Jay West, Ph.D., CEO and co-founder of BioSkryb. "With our ResolveDNA products, researchers can accurately and efficiently decipher genetic diversity at the cellular level to make transformative discoveries that improve human health."
Whole genome amplification (WGA) is required for low-input DNA and single-cell analysis, but current WGA technologies only cover a fraction of the genome and have a limited capacity to detect genetic variation in each cell. BioSkryb’s novel PTA technology accurately calls variants in genomes and reproducibly captures more than 95% of the genomes of single cells in a more consistent and accurate manner than existing approaches.
Susan Nichols, CEO of Falcon Therapeutics said, "The BioSkryb team was a great partner in assisting us with single-cell sequencing and analysis. They were responsive to our unique needs and we felt confident in the high quality of the sequencing data and analysis that we received. The results and insights their technology provided far exceeded our expectations, and BioSkryb’s commitment to supporting us in our fight against cancer using cell and gene therapies was present every step of the way."
ResolveDNA™ kits form the core of whole genome sequencing workflows, enabling single-nucleotide variant (SNV) and copy number variant (CNV) analysis in application areas such as cancer genomics, cardiology, neurology, immunology, toxicology, and preimplantation genetic testing. The kits contain all the enzymes and reagents needed for versatile and scalable whole genome amplification from single cells or ultra-low DNA inputs.
BioSkryb offers an end-to-end workflow solution, including TrailBlazer™, a cloud-based bioinformatics platform that allows users to explore single-cell human genomic datasets generated with ResolveDNA™ products. TrailBlazer access is included with the purchase of a kit or the use of BioSkryb custom services.
BioSkryb is a venture-backed developer of genomic amplification technologies based in Durham, North Carolina. Their proprietary Primary Template-directed Amplification (PTA) system delivers reproducible, high coverage breadth, and uniformity for various low or ultra-low input sequencing applications. BioSkryb’s solutions support sequencing library generation produced from limiting samples that have undergone whole genome amplification, resulting in the highest quality genetic analyses available today. For more information, please visit: https://www.bioskryb.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005234/en/